T-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating combination chemotherapy with nelarabine for T-cell acute lymphoblastic leukemia and T-cell lymphoblasti…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating adding daratumumab to standard chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia an…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma [Phase 1]
Phase 1 study evaluating anti-CD7 CAR-T cells in relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoma is currently recruiting…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma [Phase 1]
A Phase 1 trial evaluating Anti-CCR9 CAR T Cells for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma is currently recr…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) [Phase 1]
Phase 1 study of a CD70-targeted chimeric antigen receptor (CAR) T-cell therapy named SEVENTY for acute leukemias; the trial is not yet recr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating SupCD7 CAR T-cell therapy for relapsed or refractory CD7-positive hematologic malignancies is cu…
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT [Phase 1]
A Phase 1 clinical trial is evaluating CD7-targeted CAR-T therapy for patients with MRD-positive T-cell acute lymphoblastic leukemia or lymp…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma [Phase 2]
PA3-17 is being evaluated in a Phase 2 trial for adults with CD7-positive relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL [Phase 1, Phase 2]
An ongoing Phase 1/2 pediatric trial evaluating CD7-targeted CAR-T cells for relapsed/refractory CD7-positive T-cell acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation [Phase 2]
A Phase 2 clinical trial is evaluating the feasibility and safety of donor-derived natural killer cell infusions to prevent leukemia relapse…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies [Phase 1, Phase 2]
A multicenter Phase 1/2 open-label, single-arm study evaluating nanobody-based CD5-CAR T cell therapy for relapsed/refractory T-cell maligna…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating autologous and donor-derived CD7 CAR-T cell therapy for refractory or relapsed T-cell malignancies,…
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells [Phase 1]
A Phase 1 clinical trial evaluates CD7-targeted CAR-T cells derived from autologous T cells for high-risk T-cell malignancies and is current…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL [Phase 3]
A Phase 3 clinical trial evaluating targeted drugs combined with chemotherapy for T-cell acute lymphoblastic leukemia is currently recruitin…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen [Phase 1]
Phase 1 trial evaluating autologous CD5-targeted CAR T cells for T-cell malignancies expressing CD5, currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Newly-diagnosed Pediatric T-cell ALL Protocol [Phase 2, Phase 3]
This clinical trial update describes a pediatric protocol for newly diagnosed T-cell acute lymphoblastic leukemia entering Phase 2/3 and cur…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating OBI-3424 in patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, …
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" [Phase 2]
An ongoing Phase 2 trial is evaluating Daratumumab (Darzalex) for residual disease in T-cell acute lymphoblastic leukemia, with recruiting s…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations [Phase 2]
Phase 2 trial evaluating the combination of venetoclax and azacitidine for newly diagnosed early T-cell precursor acute lymphoblastic leukem…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia [EARLY_Phase 1]
This clinical trial update reports on an early-phase (Phase 1) study evaluating the safety and efficacy of the investigational therapy VGO-C…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention [Phase 2]
A Phase 2 clinical trial is evaluating a combination of demethylating agents with venetoclax to prevent relapse in patients with high-risk T…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]
Phase 1 clinical trial assessing a preventive therapy to reduce graft-versus-host disease in participants with hematologic malignancies unde…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial evaluating a CD5-targeted CAR-NK cell therapy for relapsed/refractory T-cell hematologic malignancies (T-ALL and T-ce…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a nanobody-based anti-CD5 CAR-T cell therapy for relapsed/refractory precursor T-cell lymphoblastic leukemia/ly…